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Abstract
Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a very varied spectrum of clinical manifestations that
could be partly determined by genetic factors. We aimed to determine the relationship between prevalence of 11 clinical
features and age of disease onset with European population genetic substructure. Data from 1413 patients of European
ancestry recruited in nine countries was tested for association with genotypes of top ancestry informative markers. This
analysis was done with logistic regression between phenotypes and genotypes or principal components extracted from
them. We used a genetic additive model and adjusted for gender and disease duration. Three clinical features showed
association with ancestry informative markers: autoantibody production defined as immunologic disorder (P= 6.861024),
oral ulcers (P= 6.961024) and photosensitivity (P= 0.002). Immunologic disorder was associated with genotypes more
common in Southern European ancestries, whereas the opposite trend was observed for photosensitivity. Oral ulcers were
specifically more common in patients of Spanish and Portuguese self-reported ancestry. These results should be taken into
account in future research and suggest new hypotheses and possible underlying mechanisms to be investigated. A first
hypothesis linking photosensitivity with variation in skin pigmentation is suggested.
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Introduction
Systemic Lupus Erythematosus is an autoimmune disease with a
very varied spectrum of clinical manifestations [1]. It can affect
multiple tissues and organs including kidneys, joints, skin, pleura
and pericardium, diverse blood cells and the nervous system. It is
also associated with a large variety of auto-antibodies and
abnormalities of the immune system. These features are not
present in all patients or at all times in the same patient. The
disease course alternates flares and periods of remission and
clinical presentation can be different in subsequent flares from the
observed previously in the same patient. This clinical heteroge-
neity poses many challenges to clinical diagnosis, treatment and
research. Unfortunately, our understanding of its causes is still very
incomplete, although it seems that genetic, environmental and
socioeconomic factors have a role.
Recent Genome Wide Association studies (GWAS) have
provided a list of more than 30 confirmed SLE susceptibility loci
[2]. Some of them have been associated with particular SLE
clinical features, but they are far to explain its clinical
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heterogeneity [3]. Other studies have pointed to a broad effect of
genetics in the form of the specific genetic background of human
subpopulations. There has been knowledge of differences in SLE
phenotype between continental ethnic groups for decades [1,4],
but only research in recent years has been able to confirm the
importance of genetic background by discriminating between
genetics and socioeconomic or environmental factors [5,6,7]. The
demonstration of an effect of genetic background in SLE
phenotype provides the foundation for exploring the possibility
that substructure within an ethnic group could influence also the
disease clinical presentation. Recent work in about 1900
European-American SLE patients seems to support this hypothesis
by showing correlation between the prevalence of some clinical
features and ancestry informative markers (AIMs) [8,9]. These
markers are SNPs that had shown in previous studies large
differences in allele frequency between Europeans from different
ancestries [10,11,12,13]. The finding of these correlations between
clinical features and European substructure is very important to
discriminate between the different factors influencing SLE
heterogeneity and it is possible it could increase our power to
identify etiological relationship for the different SLE phenotypes.
Our aim has been to explore the influence of European
population substructure in the SLE phenotype of about 1400
European SLE patients from 9 countries. Three of the 12 clinical
features analyzed, production of autoantibodies, oral ulcers and
photosensitivity, were associated with informative European AIMs
confirming the likely effect of variation in genetic background
within the European ethnicity.
Materials and Methods
Ethic statement
All patients gave their written informed consent to participate
and sample collection and study was approved by the relevant
ethics committees at each of the recruiting centres. The project
was approved by the Comite de Investigacion Clinica de Galicia
(Spain).
Patient data
Samples from 1413 European SLE patients recruited at 16
centres from nine different countries were collected as described
[14]. Patients were questioned about their ancestry and only
patients with uniform ancestry from the country of origin were
included. Data retrieved from each patient included the 11 SLE
American College of Rheumatology (ACR) classification criteria
[15], age of disease onset, disease duration and gender (Table 1).
Immunologic disorder was defined as for these critera and
included mainly anti-dsDNA or anti-Sm positive patients.
Antinuclear antibodies (ANA) were not included in the analysis
because they were almost uniformly present in all patients. Each
recruiting centre contributed a mean of 88.3 SLE patients with
range from 58 to 128 patients (Figure 1).
Genotyping of AIMs
Six AIMs were determined in the SLE patients: rs6730157,
rs382259, rs4988235, rs12203592, rs354690 and rs12913832. The
three first are the most informative AIMs in differentiating Northern
from Southern European subpopulations identified in a study
analyzing 300 000 SNPs in 4000 European subjects [11]. Results
from rs4988235 were not used for analysis because it was largely
redundant with rs6730157 in our samples (r2 = 0.87). rs12203592,
rs354690 are the two AIMs more informative for East-West place of
origin inside Europe according to the same study [11]. rs12913832
is a SNP associated with large differences in frequency across
Europe and unrelated with the previous [10]. These 5 SNPs were
amplified in a single PCR reaction done with the KAPA2G fast
HotStart (Kapa Biosystems, Woburn MA, USA) on a final volume
of 10 ml ( 20 ng genomic DNA) , using 3 mM MgCl2 and 0.2 mM of
each primer. Products were purified by Exo-SAP digestion with
Exonuclease I (Epicentre, Madison, WI) and Shrimp Alkaline
Figure 1. Collections of SLE patients with number of patients
available for analysis.
doi:10.1371/journal.pone.0029033.g001
Table 1. Clinical characteristics of the patients with SLE.
Characteristica % (95% C.I.) mean ± S.D.
Women 89.5 (87.9–91.1)
Age of onset 31.1613.1
Disease duration 11.968.3
Malar rash 55.7 (53.0–58.4)
Discoid rash 17.8 (15.8–19.8)
Photosensitivity 52.4 (49.7–55.1)
Oral ulcers 28.0 (25.6–30.4)
Arthritis 80.3 (78.2–82.4)
Serositis 35.5 (33.0–38.0)
Renal disorder 40.5 (37.9–43.1)
Neurologic disorder 13.6 (11.8–15.5)
Hematological disorder 71.3 (68.9–73.7)
Immunological disorderb 78.7 (76.5–80.9)
ANA 91.4 (89.8–93.0)
aData from .98% of the patients for all characteristics except for the following:
malar rash, neurologic disorder, hematologic disorders and age of disease
onset with data from .92% of the patients; disease duration and ANAs that
were not available from two recruiting centres (available in .80%).
bDefined as for the SLE ACR classification criteria [15] including abnormal anti
native DNA, anti-Sm antibodies, LE cells or false positive serologic syphilis test.
doi:10.1371/journal.pone.0029033.t001
European Subgroups in Systemic Lupus Erythematosus
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e29033
Phophatase (GE Healthcare, Barcelona, Spain). Subsequently,
single-base extension reactions with the SNaPshot Multiplex kit
(Applied Biosystems, Foster City, CA) were done. Samples were
analyzed in an AbiPrism 3130xl Genetic Analyzer (Applied
Biosystems). Genotyping call rate success was 99.7%. Sequences
of primers and probes are available from the authors upon request.
Statistical analysis
We have computed the allelic frequencies of the AIMs per each
of the 16 recruiting centres to assess their variability and whether
they follow the previously reported trends along Europe.
Concordance of these genotypes with Hardy-Weinberg equilibri-
um (HWE) was also assessed by each of the centres given that one
of the causes of deviation is population stratification and the AIMs
have population specific frequencies. The P value for claiming
deviation from HWE was set at 0.01, a conservative threshold
taking into account the number of centres and AIMs. Factor
analysis via principal component (PC) extraction was applied to
the AIM genotypes to reduce dimensionality. Association of each
of the ACR classification criteria with each of the AIMs and with
the retained principal components was analyzed by logistic
regression. Genotypes were coded according to an additive model
(0, 1 and 2, for the common homozygote, the heterozygote and the
rare homozygote genotypes, respectively). The results that are
presented included gender and disease duration as covariates. The
odds ratio by each allele (O.R.) and their 95% confidence intervals
(C.I.) are also given. Analysis of association of age of disease onset
with the AIMs genotypes or with the PC was done with multiple
linear regression. Genotypes were coded in a similar way, and
gender was included as a covariate in these analyses. Analyses
were also conducted with inclusion of the recruitment centre as
covariate and without any covariates and if results changed
interpretation, this circumstance was reported. All statistical
analyses were done with Statistica 7.0 (StatSoft, Inc., Tulsa,
OA). A significance threshold of 0.008 was applied according to a
Bonferroni correction for the six AIMs analyzed.
Results
AIM genotypes and population substructure
None of the five AIMs was significantly deviated from HWE in
any of the sample collections (P.0.01). They showed a large
variation between patients with different self-reported ancestry
within Europe (Table 2). The most extreme difference was
observed for rs6730157 that showed an A allelic frequency of
15.5% in Greek patients, and of 73.6% in Dutch patients. The
most restricted range of frequencies was observed for rs354690
(from 37.1% to 45.9% frequency of the T allele). Three of the
AIMs, rs6730157, rs12913832 and rs382259, showed a clear
differentiation between patients from Southern European coun-
tries (Portugal, Spain, Italy and Greece) and those from Central
Europe (The Netherlands, Germany, Czech Republic, Slovakia
and Hungary). This is in agreement with major axis of known
European population substructure [11,12,13].
We applied factor analysis to the genotypes of the five AIMs and
two PC explaining 46.5% of the variance were retained.
Rs6730157 was the main contributor to PC1, whereas
rs12203592 was the main contributor to PC2. These PC showed
significant correlations with the geographical coordinates of the
patient’s ancestries (Table 3): PC1 with the latitude (r =20.47)
but not with the longitude; and PC2 correlated with both the
latitude (r =20.13) and the longitude (r = 0.10). Some of the
individual AIMs showed a stronger correlation with these
coordinates than others and the correlations were particularly
strong with latitude (Table 3).
Association of SLE clinical features with population
substructure
Once we had confirmed that the five AIMs were informative for
European population substructure in our patients, we used them to
look for evidence of its effects in the phenotype of SLE. Three of
the ACR classification criteria showed association with some
AIMs. The presence of the immunological disorder criterion,
which consists in production of a variety of specific autoantibodies
(mainly anti-dsDNA or anti-Sm antibodies), was associated with
rs382259 (P= 6.861024; O.R. = 0.70, 95% C.I. = 0.57–0.86).
Increased prevalence of immunological disorder was associated
with the CC and TC genotypes of rs3822259 (Figure 2).
Association was also found between immunological disorder and
PC1 (P= 0.004; O.R. = 0.82, 95% C.I. = 0.72–0.94).
Oral ulcers were also associated with two AIMS: rs12913832
(P= 6.961024; O.R. = 0.73, 95% C.I. = 0.61–0.87) and rs382259
(P= 9.361024; O.R. = 0.72, 95% C.I. = 0.59–0.87) in single AIM
analyses. Association with these two AIMs persisted in multivariate
analysis that included the five AIMs (P= 2.061024 and
P= 1.761023, respectively) indicating that each of the two AIMs
have an independent contribution to the association. Higher
prevalence of oral ulcers was associated with the AA and GA
genotypes of rs12913832, and with the TT but not with the TC
genotypes of rs382259 (Figure 2). No association with the PCs
Table 2. Allele frequency of the ancestry informative markers (AIMs) by country of self-reported ancestry.
Countrya rs6730157 A rs12913832 G rs382259 T rs12203592 T rs354690 T
Greece 0.155 0.367 0.439 0.037 0.452
Italy 0.160 0.417 0.485 0.113 0.435
Portugal 0.386 0.258 0.689 0.075 0.409
Slovakia 0.403 0.699 0.688 0.102 0.441
Hungary 0.426 0.670 0.646 0.084 0.371
Spain 0.430 0.329 0.678 0.145 0.407
Czech R. 0.479 0.792 0.768 0.149 0.459
Germany 0.578 0.767 0.698 0.121 0.397
Netherlands 0.736 0.808 0.798 0.067 0.4237
aCountries are ordered according to allele frequencies of rs6730157. The SNPs are from most variable to less variable, left to right.
doi:10.1371/journal.pone.0029033.t002
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was observed. Analysis including the recruiting centers as
covariates showed that association with the two AIMs was
completely dependent on this factor. This was due to the higher
frequency of oral ulcers in patients from Spain and Portugal
according to their self-reported ancestry than in patients from
other origins (47.1% versus 18.5%; P,1026).
Finally, photosensitivity was associated with rs12203592
(P= 0.0021; O.R. = 1.47, 95% C.I. = 1.15–1.88). This association
was independent of conditional analysis with the other four AIMs
(P= 0.001). Photosensitivity was more common in patients that
were TT or CT for rs12203592 or (Figure 2).
The remaining SLE ACR criteria and the age of disease onset
were not associated with any AIM or PC.
Discussion
Our results have confirmed a significant effect of European
population substructure on the SLE phenotype. The substructure
associated phenotypes, immunological disorder, oral ulcers and
photosensitivity, have already been identified in the only other
group of SLE patients in which this possibility has been tested
[8,9]. The consistency of results adds credibility to the findings.
However, we have not replicated association of other clinical
features from the previous study and the effect on oral ulcers was
not fully convincing, either in our study or in the previous one
[8,9].
The AIMs we have used were able to show European
population substructure. Their variation was mainly marked by
the North-South differentiation that has been found in previous
studies [10,11,12,13]. This is remarkable because our analysis
included only a fraction of the many European populations used in
these studies. Of potential relevance is the lack in our study of
Scandinavian subjects or of subjects from the British Islands or
from Russia that had been included in the studies for the discovery
of the AIMs [11,12,13]. These populations that correspond to
geographical extremes to the North, West and East of the
European population could enlarge the range of AIM frequencies
and improve correlation of these frequencies with geographical
coordinates.
A limitation of the AIMs we have used is that they are not
enough for classification of individual subjects. However, we think
they were sufficient to detect a large fraction of the SLE clinical
features associated with European population substructure. This
conclusion is based in two pieces of evidence. The first is that the
three findings of our study were associated with more than one
AIM indicating a certain level of redundancy in spite of the low
correlation between the AIM genotypes (mean pairwise
r2 = 0.007). The second is that only the very top AIMs contributing
to the first two PCs for population substructure in Europeans,
according to a study with 300 000 SNPs [11], were informative in
our study: the third AIM contributing to PC1, rs4988235, showed
a high correlation with the first AIM, rs6730157 (r2 = 0.87), and
the same pattern of associations (not shown); and rs354690 that
was the second AIM for PC2 did not show association with any of
the clinical features.
Table 3. Correlation between the two first principal
components (PC) obtained from the AIM genotypes and
between each of the AIMS with the geographic coordinates of
the reported ancestries of the SLE patients.
Latitude Longitude
PC or AIM r P r P
PC1 0.47 ,1026 0.03 ns
PC2 20.13 1026 0.10 1.461024
rs6730157 0.71 0.002 20.40 ns
rs382259 20.62 0.010 0.50 0.048
rs12913832 0.91 1026 0.42 ns
rs12203592 0.20 ns 20.58 0.019
rs354690 20.07 ns 0.41 ns
doi:10.1371/journal.pone.0029033.t003
Figure 2. Frequency of the SLE clinical features associated with AIM genotypes. The abscise axis indicates the AIM genotype and in the
ordinate axis are the frequencies of the indicated clinical manifestation.
doi:10.1371/journal.pone.0029033.g002
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Association of the production of the SLE specific autoantibodies
that are included in the immunologic disorder criterion (in most
cases, antibodies to dsDNA or the nuclear Sm antigen) with
rs382259 and with PC1 indicates a role of the patient’s genetic
background. It is worth to mention that immunological disorder
was also associated with the two first PCs in the study done in
European American SLE patients [9]. This association was
interpreted as meaning that a Southern and Western European
ancestry predisposes to autoantibody production. Our results can
be interpreted also as meaning that a Southern European ancestry
predisposes to this phenotype, but no clear differentiation in the
West-East axis was observed.
The effect of genetic background in the prevalence of
autoantibodies had already been shown in relation with the
continental ethnic groups. For example, there are reports showing
an increased prevalence of anti-Sm and anti-RNP antibodies in
African patients relative to Europeans [16,17,18,19]; other
differences concern clusters of autoantibodies that include anti-
Sm or anti-dsDNA [20], or other specific SLE autoantibodies like
anti-P [21] or anti-RNA helicase A [18,22]. But, there is not any
report of a general higher prevalence of SLE autoantibodies in
patients of a specific ethnic group. On the contrary, some
autoantibodies have been found at low prevalence while others
show high prevalence in the same ethnicity [18,20,22]. Therefore,
it seems likely that genetic background is influencing specific
responses more than the general abnormalities leading to antibody
mediated autoimmunity. This could be the case for HLA alleles
whose frequency is highly variable between populations and that
affect prevalence of anti-P [21], anti-cardiolipin and anti-
beta2GPI antibodies in different ethnicities [23]. It seems likely
that differences within Europeans affect autoantibody production
in SLE patients in the same way.
The association of oral ulcers with European population
substructure is more open to question. Although we have observed
a clear association with two AIMs, rs12913832 and rs382259, it
disappeared after adjusting by center of recruitment. This result
invites to caution but does not invalidate interpretation because
centers of recruitment were strongly linked with the patient’s
reported ancestries. In fact, classifying the patients by their
reported ancestries showed a clear excess of oral ulcers in patients
from Spain and Portugal. This increased prevalence is reflected by
with the AIMs association with a higher frequency of the
associated genotypes in the South-Western European ancestries.
Results from the study on European American patients showed an
increase of oral ulcers also in patients with Southern European
ancestry, but again it did not persist after adjusting for covariates
[9]. Given these results, we cannot conclude at present. We cannot
distinguish a genuine difference in the phenotype of patients with a
South-Western European ancestry from confounding factors
associated with recruiting hospitals. In addition, there has not
been a wide interest in the analysis of variation in prevalence of
oral ulcers between SLE patients from different ethnicities. Large
differences between SLE patient series from different ethnicities
have been reported [4], but as they were not obtained in
comparative studies and have not been replicated, it is unclear
whether these differences could be attributable to genetic
background. Therefore, we lack evidence of reproducible trends
and of possible etiologic factors that could help us to interpret the
current results. However, there are data from large collections of
European SLE patients that support the difference we have found:
two collections of Spanish SLE patients showed a prevalence of
oral ulcers of 46.4% and 54.3% (of 462 and 490 patients,
respectively) [24], and a study of 544 Portuguese SLE patients
reported a prevalence of 45% [25]; whereas the Euro-Lupus study
showed a prevalence of 12.5% (of 1000 patients from all over
Europe) [26].
The third SLE clinical feature we have found associated with
European population substructure is photosensitivity. It was
associated with the genotypes of two AIMs. rs12913832 direc-
tionwas characteristic of Northern Europeans. An excess of
photosensitivity in SLE patients with Northern European ancestry
was also found in the previous study of European-Americans [8,9].
This effect of population substructure is the most amenable to
interpretation because it could be related with lighter skin
pigmentation, which has a key role in sensitivity to sunburns,
melanoma and other UV-related cancers and which is much more
common in Northern Europeans than in Southern Europeans.
This interpretation is in agreement with the lower prevalence of
SLE photosensitivity among African American patients with SLE
[19], or black patients from South Africa [27] or Jamaica [28].
However, rs12203592 was also associated with photosensitivity
without any discernible geographical frequency distribution, and
no studies of skin pigmentation or phototype in relation with SLE
photosensitivity have been done in Europeans. Therefore, this
hypothesis requires specific testing. It could be done directly by
comparing prevalence of photosensitivity in function of skin color
and sun exposure, but also by looking for association between the
wide array of loci already known to determine skin pigmentation,
which show wide differences in frequency among Europeans
[10,29], and SLE photosensitivity.
Other SLE clinical features showed association with European
population substructure in the Richman et al. study [9], but not in
our study and, therefore, they remain unconfirmed. These include
discoid rash, renal disorder, serositis, neurological disorder and
malar rash. Some of them were weakly associated in the Richman
study, like malar rash and neurological disorder, but the others
showed P values below 0.01. These differences could be due to
lack of power of our study, false positive findings in the Richman
study or to differences between SLE patients and study design of
the two reports. For example, our study included a high fraction of
subject with self-reported ancestry from Southern European
countries followed by Central European countries, whereas the
European American patients were very markedly of Northern and
Western European ancestry [8].
As has been commented already, the clinical features associated
with European populations substructure could be due to their
relation with SLE loci that show a frequency gradient within
Europe. Apart from the HLA alleles [30], we know already of
other differences in SLE associated loci between Europeans from
different ancestries. The SLE risk allele of PTPN22 R620W shows
a higher frequency in subjects from the North and West of Europe
than in those from the South [31]. Our Consortium has also
shown that a difference in frequencies, although more complex, is
present for PD1.3, a SLE risk polymorphism the PDCD1 locus
[32,33]. The A allele is more common in SLE patients than in
controls from the North Center of Europe, similar in patients and
controls from the Southeast, and more common in controls than in
SLE patients from the Southwest of Europe [33]. Notably, the
gradient in frequency has been observed only in controls, not in
patients. It is possible than these and similar variations in risk allele
frequencies explain the associations between SLE clinical features
and European population substructure.
One of the limitations of our study is that it does not include a
representative sample of SLE patients from all the countries with
European ancestry. It will be also desirable to include in the
analysis other important characteristics of SLE besides the ACR
classification criteria like additional clinical manifestations or any
of the damage or disease activity indexes. It will be also beneficial
European Subgroups in Systemic Lupus Erythematosus
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to count with more detailed information about autoantibodies or
severity of the different clinical features. A concerted effort will be
necessary to obtain this type of high quality data from a large
number of patients of multiple European ancestries.
We have not corrected the P values for number clinical features
analyzed. This was motivated by the difficulty in defining an
appropriate level of correction. Two issues make this difficult: the
correlation between clinical features that will lead to overcorrec-
tion if a Bonferroni approach is used; and the contentious issue of
whether association of each clinical feature should be considered
as an independent hypothesis or as a unique hypothesis [34,35].
In summary, our study reinforces the evidence of a significant
but modest degree of variation in the SLE phenotype in relation
with European population substructure. The differences we have
found will help to understand the underlying mechanisms as clues
of possible association with particular loci and skin pigmentation
are already suggested. Elucidation of these mechanisms will
advance our ability to cope with SLE clinical heterogeneity. In
addition, this finding is important for the design of SLE clinical
projects including patients of European ancestry that until now
have been taken as a unit of study or comparison. Accounting for
European substructure will be even more important for research
aiming to define the relationships between SLE phenotype and
genotype. Specifically, our study contributes also to consolidate the
association between Southern European ancestry and more
prevalence of autoantibody production and less photosensitivity
in SLE patients and suggests the possibility of an increased
frequency of oral ulcers in patients with South-Western European
ancestry.
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